Key Highlights:
- TransMedics Group (TMDX, Financial) shares have risen significantly by 20% over the past month.
- Analysts set a promising consensus target of $102.86, driven by advancements in heart and lung technology.
- GuruFocus estimates suggest a remarkable potential upside of 227.86% based on the current evaluation.
TransMedics Group's Recent Stock Movement
TransMedics Group (TMDX) has captured investor attention with a significant 20% surge in its stock price over the last month. Currently priced at $67.95, the stock positions itself for further appreciation, aiming towards a consensus target of $102.86. This optimism is fueled by the impending launch of its Next-Gen Heart and Lung programs, planned for 2025, which could enhance the company's market position.
Analysts' Price Targets
According to predictions from 8 analysts, the average target price for TransMedics Group (TMDX, Financial) stands at $115.63, with estimates ranging from a low of $80.00 to a high of $179.00. This average forecast suggests an impressive potential upside of 36.61% from the current stock price of $84.64. For a more in-depth exploration of these predictions, visit the TransMedics Group Inc (TMDX) Forecast page.
Brokerage Recommendations
Reflecting a strong market sentiment, TransMedics Group (TMDX, Financial) receives an "Outperform" rating, with an average brokerage recommendation score of 2.0 from 11 brokerage firms. This rating operates on a scale from 1 to 5, with 1 representing a Strong Buy and 5 indicating a Sell.
GuruFocus Valuation Insight
GuruFocus estimates project the GF Value for TransMedics Group (TMDX, Financial) to reach $277.49 within a year, suggesting a striking upside potential of 227.86% from its current price of $84.6375. This valuation reflects GuruFocus' comprehensive assessment of the fair value based on historical trading multiples, business growth, and future performance projections. For additional insights, explore the TransMedics Group Inc (TMDX) Summary page.
